Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
“Organoïden kunnen grote stap betekenen voor oncologie”
dec 2020 | Maag-darm-leveroncologie